A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations

NCT06800196 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors with FGFR2 Alterations, Adult

Interventions

DRUG: KNT-0916

Sponsor

KinoTeck Therapeutics Co., Ltd